Incyte Corporation Stock Price, News & Analysis (NASDAQ:INCY)

$98.78 -0.22 (-0.22 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$99.00
Today's Range$98.30 - $99.47
52-Week Range$96.60 - $153.15
Volume482,825 shs
Average Volume1.93 million shs
Market Capitalization$20.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.81

About Incyte Corporation (NASDAQ:INCY)

Incyte Corporation logoIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.82%
Quick Ratio4.81%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.11 billion
Price / Sales18.85
Cash Flow$0.93 per share
Price / Cash105.92
Book Value$8.33 per share
Price / Book11.86

Profitability

Trailing EPS($0.80)
Net Income$104.22 million
Net Margins-10.90%
Return on Equity-12.91%
Return on Assets-7.41%

Miscellaneous

Employees980
Outstanding Shares211,040,000

Frequently Asked Questions for Incyte Corporation (NASDAQ:INCY)

What is Incyte Corporation's stock symbol?

Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte Corporation's earnings last quarter?

Incyte Corporation (NASDAQ:INCY) announced its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.11. The biopharmaceutical company had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. Incyte Corporation had a negative net margin of 10.90% and a negative return on equity of 12.91%. Incyte Corporation's quarterly revenue was up 41.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.19 earnings per share. View Incyte Corporation's Earnings History.

When will Incyte Corporation make its next earnings announcement?

Incyte Corporation is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Incyte Corporation.

Where is Incyte Corporation's stock going? Where will Incyte Corporation's stock price be in 2017?

21 equities research analysts have issued 1 year target prices for Incyte Corporation's stock. Their forecasts range from $120.00 to $174.00. On average, they anticipate Incyte Corporation's stock price to reach $145.63 in the next twelve months. View Analyst Ratings for Incyte Corporation.

What are Wall Street analysts saying about Incyte Corporation stock?

Here are some recent quotes from research analysts about Incyte Corporation stock:

  • 1. Cowen Inc analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
  • 2. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)
  • 3. Jefferies Group LLC analysts commented, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and increasing depth from the maturing pipeline building towards broad, more diversified long-term growth opportunities. We continue to see upside potential in 2017 supported by continued Jakafi execution, IDO data/progress, and bari launch enthusiasm, with scarcity value likely continuing to drive M&A speculation. Adjust tgt to $140 from $136." (2/15/2017)

Who are some of Incyte Corporation's key competitors?

Who are Incyte Corporation's key executives?

Incyte Corporation's management team includes the folowing people:

  • Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer (Age 57)
  • David W. Gryska, Chief Financial Officer, Executive Vice President (Age 61)
  • Reid M. Huber, Executive Vice President, Chief Scientific Officer (Age 45)
  • Eric H. Siegel, Executive Vice President, General Counsel (Age 52)
  • Paula J. Swain, Executive Vice President - Human Resources (Age 59)
  • Barry P. Flannelly, Executive Vice President and General Manager , US (Age 59)
  • Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development` (Age 44)
  • Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry (Age 54)
  • Steven H. Stein M.D., Vice President and Chief Medical Officer (Age 50)
  • Julian C. Baker, Lead Independent Director (Age 50)

Who owns Incyte Corporation stock?

Incyte Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital International Investors (3.08%), Bank of New York Mellon Corp (0.79%), Jennison Associates LLC (0.77%), Manning & Napier Advisors LLC (0.51%), Pictet Asset Management Ltd. (0.51%) and American Century Companies Inc. (0.51%). Company insiders that own Incyte Corporation stock include Barry P Flannelly, Bros Advisors Lp Baker, David W Gryska, Eric H Siegel, Herve Hoppenot, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Richard S Levy and Steven H Stein. View Institutional Ownership Trends for Incyte Corporation.

Who sold Incyte Corporation stock? Who is selling Incyte Corporation stock?

Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Victory Capital Management Inc., Alyeska Investment Group L.P., Frontier Capital Management Co. LLC, KBC Group NV, Neuberger Berman Group LLC, First Trust Advisors LP and Bank of New York Mellon Corp. Company insiders that have sold Incyte Corporation company stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Herve Hoppenot, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte Corporation.

Who bought Incyte Corporation stock? Who is buying Incyte Corporation stock?

Incyte Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Old Mutual Global Investors UK Ltd., Jennison Associates LLC, Pictet Asset Management Ltd., Point72 Asset Management L.P., Capital Bank & Trust Co, Teacher Retirement System of Texas and Capital International Investors. Company insiders that have bought Incyte Corporation stock in the last two years include Bros Advisors Lp Baker, Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte Corporation.

How do I buy Incyte Corporation stock?

Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte Corporation's stock price today?

One share of Incyte Corporation stock can currently be purchased for approximately $98.78.

How big of a company is Incyte Corporation?

Incyte Corporation has a market capitalization of $20.89 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $104.22 million in net income (profit) each year or ($0.80) on an earnings per share basis. Incyte Corporation employs 980 workers across the globe.

How can I contact Incyte Corporation?

Incyte Corporation's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]


MarketBeat Community Rating for Incyte Corporation (INCY)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  835 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  1,107
MarketBeat's community ratings are surveys of what our community members think about Incyte Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Incyte Corporation (NASDAQ:INCY)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.782.782.81
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $144.25$142.55$139.50$136.84
Price Target Upside: 45.78% upside24.44% upside12.20% upside1.83% upside

Consensus Price Target History for Incyte Corporation (NASDAQ:INCY)

Price Target History for Incyte Corporation (NASDAQ:INCY)

Analysts' Ratings History for Incyte Corporation (NASDAQ:INCY)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Royal Bank Of CanadaLower Price TargetSector Perform -> Sector Perform$136.00 -> $120.00N/AView Rating Details
10/31/2017Oppenheimer Holdings, Inc.Set Price TargetHold$135.00N/AView Rating Details
10/31/2017BMO Capital MarketsBoost Price TargetOutperform$162.00 -> $166.00N/AView Rating Details
10/31/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Initiated CoverageBuy$160.00N/AView Rating Details
10/6/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
9/13/2017ArgusReiterated RatingBuy$150.00LowView Rating Details
9/11/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$159.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$135.00MediumView Rating Details
8/2/2017Barclays PLCReiterated RatingOverweight$180.00 -> $165.00LowView Rating Details
7/16/2017Credit Suisse GroupSet Price TargetBuy$152.00LowView Rating Details
7/3/2017Cowen IncReiterated RatingOutperform$130.00MediumView Rating Details
6/28/2017GabelliReiterated RatingBuy$174.00MediumView Rating Details
5/31/2017CIBCBoost Price TargetOutperform$125.00 -> $135.00LowView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00MediumView Rating Details
4/19/2017SunTrust Banks, Inc.Lower Price TargetBuy$160.00 -> $145.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
3/21/2017William BlairInitiated CoverageOutperformLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/31/2016Bank of America CorporationReiterated RatingBuy$145.00 -> $87.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Incyte Corporation (NASDAQ:INCY)

Earnings by Quarter for Incyte Corporation (NASDAQ:INCY)

Earnings History by Quarter for Incyte Corporation (NASDAQ INCY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$0.01N/AView Earnings Details
10/31/2017Q3 2017$0.06$0.17$360.34 million$381.50 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.05)($0.06)$318.45 million$326.40 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Incyte Corporation (NASDAQ:INCY)
2017 EPS Consensus Estimate: ($0.60)
2018 EPS Consensus Estimate: $0.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.01)($0.82)($0.93)
Q2 20175($0.08)$0.61$0.28
Q3 20176($0.08)$0.32$0.08
Q4 20176($0.59)$0.22($0.03)
Q1 20181($0.21)($0.21)($0.21)
Q2 20182($0.06)$0.04($0.01)
Q3 20182$0.16$0.47$0.32
Q4 20182$0.08$0.10$0.09
Q2 20191$0.65$0.65$0.65
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Incyte Corporation (NASDAQ:INCY)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Incyte Corporation (NASDAQ INCY)

Insider Ownership Percentage: 17.70%
Institutional Ownership Percentage: 89.60%
Insider Trades by Quarter for Incyte Corporation (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Insider Trades by Quarter for Incyte Corporation (NASDAQ INCY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017Paul A FriedmanDirectorSell28,507$105.24$3,000,076.68View SEC Filing  
11/2/2017David W GryskaInsiderSell3,915$105.63$413,541.45View SEC Filing  
9/18/2017Herve HoppenotPresidentSell70,502$119.45$8,421,463.90View SEC Filing  
9/14/2017Barry P FlannellyEVPSell714$124.25$88,714.50View SEC Filing  
9/8/2017Bros. Advisors Lp BakerDirectorBuy100,000$132.00$13,200,000.00View SEC Filing  
9/5/2017Paul TrowerInsiderSell3,000$138.41$415,230.00View SEC Filing  
9/1/2017Eric H SiegelEVPSell1,820$137.40$250,068.00View SEC Filing  
8/31/2017Paula J SwainEVPSell20,000$140.00$2,800,000.00View SEC Filing  
8/29/2017Steven H SteinEVPSell2,111$125.00$263,875.00View SEC Filing  
8/4/2017Paul TrowerInsiderSell3,000$125.25$375,750.00View SEC Filing  
8/1/2017Eric H SiegelEVPSell1,820$132.92$241,914.40View SEC Filing  
7/20/2017Steven H SteinEVPSell6,485$131.09$850,118.65View SEC Filing  
7/5/2017Paul TrowerInsiderSell3,000$126.18$378,540.00View SEC Filing  
7/3/2017Eric H SiegelEVPSell1,820$126.20$229,684.00View SEC Filing  
6/30/2017David W GryskaInsiderSell599$129.74$77,714.26View SEC Filing  
6/20/2017Steven H SteinEVPSell9,883$125.00$1,235,375.00View SEC Filing  
6/12/2017David W GryskaCFOSell16,756$116.60$1,953,749.60View SEC Filing  
6/5/2017Paul TrowerInsiderSell3,000$132.50$397,500.00View SEC Filing  
6/1/2017Eric H SiegelEVPSell1,820$130.00$236,600.00View SEC Filing  
5/31/2017Jean Jacques BienaimeDirectorBuy500$131.80$65,900.00View SEC Filing  
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.00View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.17View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.60View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.00View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.00View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.00View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.74View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.00View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.00View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.00View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Incyte Corporation (NASDAQ INCY)

Source:
DateHeadline
FY2021 EPS Estimates for Incyte Corporation (INCY) Lowered by GabelliFY2021 EPS Estimates for Incyte Corporation (INCY) Lowered by Gabelli
www.americanbankingnews.com - November 23 at 10:08 PM
Incyte Co. (INCY) PT Lowered to $120.00 at Royal Bank Of CanadaIncyte Co. (INCY) PT Lowered to $120.00 at Royal Bank Of Canada
www.americanbankingnews.com - November 21 at 8:58 PM
Incyte Corporation 2017 Q3 - Results - Earnings Call SlidesIncyte Corporation 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 21 at 12:41 AM
Paul A. Friedman Sells 28,507 Shares of Incyte Corporation (INCY) StockPaul A. Friedman Sells 28,507 Shares of Incyte Corporation (INCY) Stock
www.americanbankingnews.com - November 20 at 7:36 PM
Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi - Business Wire (press release)Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi - Business Wire (press release)
www.businesswire.com - November 17 at 6:50 AM
Analyzing Incyte Corporation (INCY) and Its RivalsAnalyzing Incyte Corporation (INCY) and Its Rivals
www.americanbankingnews.com - November 17 at 1:24 AM
Incyte Corporation (INCY) and Abeona Therapeutics (ABEO) Head-To-Head ComparisonIncyte Corporation (INCY) and Abeona Therapeutics (ABEO) Head-To-Head Comparison
www.americanbankingnews.com - November 14 at 3:40 PM
$411.23 Million in Sales Expected for Incyte Corporation (INCY) This Quarter$411.23 Million in Sales Expected for Incyte Corporation (INCY) This Quarter
www.americanbankingnews.com - November 9 at 4:52 PM
Lightning Round: Jim Cramer Gives His Opinion On Incyte, Apache And More - BenzingaLightning Round: Jim Cramer Gives His Opinion On Incyte, Apache And More - Benzinga
www.benzinga.com - November 8 at 10:25 AM
Cramers lightning round: Dont give up on Incyte - CNBC.com - CNBCCramer's lightning round: Don't give up on Incyte - CNBC.com - CNBC
www.cnbc.com - November 8 at 10:25 AM
Zacks: Analysts Anticipate Incyte Corporation (INCY) Will Announce Earnings of -$0.37 Per ShareZacks: Analysts Anticipate Incyte Corporation (INCY) Will Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - November 7 at 1:26 AM
Vapid Earnings Visibility Restrict Incyte (INCY) RatingVapid Earnings Visibility Restrict Incyte (INCY) Rating
investorplace.com - November 6 at 8:43 PM
Incyte Corporation to Post Q4 2017 Earnings of ($0.59) Per Share, William Blair Forecasts (INCY)Incyte Corporation to Post Q4 2017 Earnings of ($0.59) Per Share, William Blair Forecasts (INCY)
www.americanbankingnews.com - November 6 at 8:40 AM
FY2017 Earnings Forecast for Incyte Corporation Issued By Gabelli (INCY)FY2017 Earnings Forecast for Incyte Corporation Issued By Gabelli (INCY)
www.americanbankingnews.com - November 6 at 4:38 AM
Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 2:18 AM
Incyte Corporation (INCY) & Its Peers Critical AnalysisIncyte Corporation (INCY) & Its Peers Critical Analysis
www.americanbankingnews.com - November 3 at 9:14 PM
David W. Gryska Sells 3,915 Shares of Incyte Corporation (INCY) StockDavid W. Gryska Sells 3,915 Shares of Incyte Corporation (INCY) Stock
www.americanbankingnews.com - November 3 at 5:42 PM
Oversold Conditions For IncyteOversold Conditions For Incyte
www.forbes.com - November 3 at 9:56 AM
FY2021 EPS Estimates for Incyte Corporation (INCY) Cut by AnalystFY2021 EPS Estimates for Incyte Corporation (INCY) Cut by Analyst
www.americanbankingnews.com - November 2 at 5:34 PM
Oppenheimer Holdings Research Analysts Lift Earnings Estimates for Incyte Corporation (INCY)Oppenheimer Holdings Research Analysts Lift Earnings Estimates for Incyte Corporation (INCY)
www.americanbankingnews.com - November 2 at 5:34 PM
Q4 2018 Earnings Estimate for Incyte Corporation Issued By William Blair (INCY)Q4 2018 Earnings Estimate for Incyte Corporation Issued By William Blair (INCY)
www.americanbankingnews.com - November 2 at 4:40 PM
Q2 2018 Earnings Forecast for Incyte Corporation (INCY) Issued By SunTrust BanksQ2 2018 Earnings Forecast for Incyte Corporation (INCY) Issued By SunTrust Banks
www.americanbankingnews.com - November 2 at 2:33 PM
BRIEF-Incyte says Q3 earnings per share $0.17BRIEF-Incyte says Q3 earnings per share $0.17
www.businessinsider.com - November 2 at 2:19 AM
Incyte (INCY) Says More Than 30 Abstracts Highlighting Data from its Portfolio Accepted for Presentation at ASHIncyte (INCY) Says More Than 30 Abstracts Highlighting Data from its Portfolio Accepted for Presentation at ASH
www.streetinsider.com - November 2 at 2:19 AM
More Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59 th Annual ASH MeetingMore Than 30 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 59 th Annual ASH Meeting
www.businesswire.com - November 2 at 2:19 AM
Heres What Was Intriguing About Incytes Q3 ReportHere's What Was Intriguing About Incyte's Q3 Report
www.benzinga.com - November 2 at 2:19 AM
Buy the dip in Incyte - Credit SuisseBuy the dip in Incyte - Credit Suisse
seekingalpha.com - November 1 at 3:50 PM
Incyte (INCY) Q3 2017 Results - Earnings Call Transcript | Seeking ... - Seeking AlphaIncyte (INCY) Q3 2017 Results - Earnings Call Transcript | Seeking ... - Seeking Alpha
seekingalpha.com - October 31 at 10:35 PM
Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early ... - Business Wire (press release)Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early ... - Business Wire (press release)
www.businesswire.com - October 31 at 10:35 PM
Incyte Corporation (INCY) PT Raised to $166.00Incyte Corporation (INCY) PT Raised to $166.00
www.americanbankingnews.com - October 31 at 7:18 PM
Incyte Corporation (INCY) Given Buy Rating at J P Morgan Chase & CoIncyte Corporation (INCY) Given Buy Rating at J P Morgan Chase & Co
www.americanbankingnews.com - October 31 at 3:25 PM
Incyte Corporation (INCY) Releases Quarterly  Earnings Results, Beats Expectations By $0.11 EPSIncyte Corporation (INCY) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS
www.americanbankingnews.com - October 31 at 8:56 AM
Incyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to BoardIncyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to Board
www.streetinsider.com - October 31 at 3:14 AM
Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung CancerIncyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer
finance.yahoo.com - October 31 at 3:14 AM
Incyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to Board - StreetInsider.comIncyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to Board - StreetInsider.com
www.streetinsider.com - October 30 at 10:11 PM
Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody ... - Business Wire (press release)Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody ... - Business Wire (press release)
www.businesswire.com - October 26 at 1:50 PM
Incyte Corporation (INCY) Stock Rating Reaffirmed by J P Morgan Chase & CoIncyte Corporation (INCY) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - October 26 at 1:34 PM
Incyte Corporation (INCY) to Release Quarterly Earnings on TuesdayIncyte Corporation (INCY) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 24 at 1:16 PM
Head-To-Head Analysis: Cellectis (CLLS) vs. Incyte Corporation (INCY)Head-To-Head Analysis: Cellectis (CLLS) vs. Incyte Corporation (INCY)
www.americanbankingnews.com - October 23 at 12:54 PM
$359.48 Million in Sales Expected for Incyte Corporation (INCY) This Quarter$359.48 Million in Sales Expected for Incyte Corporation (INCY) This Quarter
www.americanbankingnews.com - October 20 at 7:22 AM
USPTO rejects Incytes challenge to Concert Pharma patent; shares up 5%USPTO rejects Incyte's challenge to Concert Pharma patent; shares up 5%
seekingalpha.com - October 19 at 1:55 PM
Incyte Cancer Treatment Uses Patients' Immune System To Fight DiseaseIncyte Cancer Treatment Uses Patients' Immune System To Fight Disease
finance.yahoo.com - October 16 at 3:37 PM
ETFs with exposure to Incyte Corp. : October 16, 2017ETFs with exposure to Incyte Corp. : October 16, 2017
finance.yahoo.com - October 16 at 3:37 PM
Leerink Swann Weighs in on Incyte Corporations Q3 2017 Earnings (INCY)Leerink Swann Weighs in on Incyte Corporation's Q3 2017 Earnings (INCY)
www.americanbankingnews.com - October 12 at 7:56 AM
Incyte: No Major Catalyst, Rising Expenses, Stretched Valuation - Seeking AlphaIncyte: No Major Catalyst, Rising Expenses, Stretched Valuation - Seeking Alpha
seekingalpha.com - October 12 at 6:24 AM
Incyte Corporation (INCY) Receives Consensus Recommendation of "Buy" from AnalystsIncyte Corporation (INCY) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 11 at 2:40 PM
Research Analysts Set Expectations for Incyte Corporations Q4 2017 Earnings (INCY)Research Analysts Set Expectations for Incyte Corporation's Q4 2017 Earnings (INCY)
www.americanbankingnews.com - October 11 at 9:20 AM
Merus to Participate in the BIO Investor ForumMerus to Participate in the BIO Investor Forum
globenewswire.com - October 10 at 7:16 PM
Incyte Corporation (INCY) Now Covered by Analysts at Goldman Sachs Group, Inc. (The)Incyte Corporation (INCY) Now Covered by Analysts at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 7 at 12:58 AM
Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance ... - Business Wire (press release)Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance ... - Business Wire (press release)
www.businesswire.com - October 6 at 11:26 PM

Social Media

Financials

Chart

Incyte Corporation (NASDAQ INCY) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.